All In Biotech

NDA 021286 · Cosette

Benicar

Olmesartan Medoxomil · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Oct 17, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Apr 25, 2002

Approved uses

2

Original approval plus efficacy supplements

Registered trials

141

56 Phase 3, 4 recruiting

FAERS reports

36,093

23,598 serious, 1,635 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Benicar as soon as possible ( 5.1 , 8.1 ). Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.1 , 8.1 ). WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Benicar as soon as possible ( 5.1 , 8.1 ). Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.1 , 8.1 ).

What it is approved for

From the label in effect Sep 23, 2025.

Benicar is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at...

Mechanism: Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in vascular smooth muscle. Its action is, therefore, independent of the pathways for angiotensin II...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • BENICAR · OLMESARTAN MEDOXOMIL 20MG · TABLET, ORAL · Prescription · TE AB
  • BENICAR · OLMESARTAN MEDOXOMIL 5MG · TABLET, ORAL · Prescription · TE AB
  • BENICAR · OLMESARTAN MEDOXOMIL 40MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Olmesartan Medoxomil" as an intervention, any sponsor and status, largest first.

All 141 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • sprue-like enteropathy3,497
  • diarrhoea2,512
  • weight decreased2,231
  • dizziness2,127
  • gastrooesophageal reflux disease2,079
  • nausea2,059
  • acute kidney injury2,028
  • drug ineffective1,997
  • fatigue1,702
  • headache1,428
  • haemorrhoids1,369
  • dyspnoea1,362

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004486
2005567
2006572
2007777
20081,069
20091,285
20101,815
20111,741
20121,930
20131,205
20141,455
20152,878
20162,914
20173,142
20183,211
20192,113
20201,373
20211,203
20221,537
20231,436
20241,168
20251,210
20261,006

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Benicar (Olmesartan Medoxomil)

2024 spending

$14.0M

Beneficiaries

4,009

19,325 claims

Per beneficiary

$3,493

$11.30 per unit

View as table
YearSpending
2020$20,401,793
2021$18,176,654
2022$16,185,464
2023$15,710,812
2024$14,002,739

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 145 on PubMed

Sponsor: Cosette

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.